UNSPSC 51314339: Chlorpheniramine/guaifenesin/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314339 Chlorpheniramine/guaifenesin/phenylephrine is a Commodity code that in recent state and local procurement activity does not align with the code's nominal scope. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which match the specific combination decongestant and antihistamine represented by the code name. The issuing bodies span county health departments, state health agencies, and cooperative purchasing alliances, indicating a mix of direct procurement and vendor-aggregation models across different tiers of government. The code appears to show little relevant recent activity in its stated pharmaceutical category, and the mismatch between the code and posted opportunities suggests either miscategorization at posting or broader pharmaceutical procurement being tagged under a narrow commodity code.

The geographic spread of recent activity includes Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP, which serves multiple states including Oregon). Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (the due date appears to predate the posting date in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, as an exploratory market-intelligence inquiry into direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products across member states, with proposals due March 26, 2026, and awarded vendors to be effective July 1, 2026. The code shows procurement activity but does not demonstrate substantive recent opportunities aligned with its stated pharmaceutical classification.